Advair Diskus 250 [Fluticasone Propionate + Salmeterol inhalation powder 250mcg | 50mcg x 60 doses] CANADIAN PHARMACEUTICAL GRADE

ADVAIR DISKUS 250 [FLUTICASONE PROPIONATE + SALMETEROL INHALATION POWDER 250MCG | 50MCG X 60 DOSES] – CANADIAN PHARMACEUTICAL GRADE COMBINATION RESEARCH INHALER

Advair Diskus 250 contains a dual-active combination of Fluticasone Propionate (250mcg) and Salmeterol (50mcg) per inhalation dose. It is a Canadian pharmaceutical grade dry powder inhalation system designed for research applications focused on respiratory receptor modulation, anti-inflammatory activity, and beta-2 adrenergic pathway studies.

Researchers use this formulation to evaluate the synergistic effects between corticosteroid-mediated anti-inflammatory signaling and beta-2 adrenergic receptor agonism within controlled pulmonary systems. Each device provides 60 precisely metered doses in a sealed, dry-powder delivery system.

The Details:

• Active Ingredients: Fluticasone Propionate 250mcg + Salmeterol Xinafoate 50mcg per dose

• Quantity: 60 metered doses per Diskus device

• Form: Inhalation powder (Dry Powder Inhaler – DPI)

• Packaging: Tamper-evident sealed unit for stability and integrity

• Source: Canadian pharmaceutical grade, independently verified for potency and composition

Key Features of Advair Diskus 250:

• Dual Mechanism Research Tool: Combines corticosteroid and beta-2 agonist for receptor pathway comparison.

• Anti-Inflammatory Studies: Supports investigations into glucocorticoid receptor signaling and cytokine modulation.

• Adrenergic Pathway Research: Enables analysis of long-acting beta-2 receptor engagement.

• Synergistic Modeling: Designed for combined pathway studies in pulmonary response experiments.

• Canadian Verified Quality: Produced to pharmaceutical standards and third-party verified.

For more products, visit: https://www.canadasteroiddepot.is/